Skip to content
Agree.net – Lifestyle
Author:
ZENTALIS PHARMACEUTICALS
Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer
April 9, 2026
Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026
March 17, 2026
←
Previous Page
1
2
3